Rübsam, A.; Hössl, L.; Rau, S.; Böker, A.; Zeitz, O.; Joussen, A.M.
Real-World Experience with Brolucizumab Compared to Aflibercept in Treatment-Naïve and Therapy-Refractory Patients with Diabetic Macular Edema. J. Clin. Med. 2024, 13, 1819.
https://doi.org/10.3390/jcm13061819
AMA Style
Rübsam A, Hössl L, Rau S, Böker A, Zeitz O, Joussen AM.
Real-World Experience with Brolucizumab Compared to Aflibercept in Treatment-Naïve and Therapy-Refractory Patients with Diabetic Macular Edema. Journal of Clinical Medicine. 2024; 13(6):1819.
https://doi.org/10.3390/jcm13061819
Chicago/Turabian Style
Rübsam, Anne, Leopold Hössl, Saskia Rau, Alexander Böker, Oliver Zeitz, and Antonia M. Joussen.
2024. "Real-World Experience with Brolucizumab Compared to Aflibercept in Treatment-Naïve and Therapy-Refractory Patients with Diabetic Macular Edema" Journal of Clinical Medicine 13, no. 6: 1819.
https://doi.org/10.3390/jcm13061819
APA Style
Rübsam, A., Hössl, L., Rau, S., Böker, A., Zeitz, O., & Joussen, A. M.
(2024). Real-World Experience with Brolucizumab Compared to Aflibercept in Treatment-Naïve and Therapy-Refractory Patients with Diabetic Macular Edema. Journal of Clinical Medicine, 13(6), 1819.
https://doi.org/10.3390/jcm13061819